The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Chemical genetic strategy for targeting protein kinases based on covalent complementarity
Abstract
The conserved nature of the ATP-binding site of the > 500 human kinases renders the development of specific inhibitors a challenging task. A widely used chemical genetic strategy to overcome the specificity challenge exploits a large-to-small mutation of the gatekeeper residue (a conserved hydrophobic amino acid) and the use of a bulky inhibitor to achieve specificity via shape complementarity. However, in a number of cases, introduction of a glycine or alanine gatekeeper results in diminished kinase activity and ATP affinity. A new chemical genetic approach based on covalent complementarity between an engineered gatekeeper cysteine and an electrophilic inhibitor was developed to address these challenges. This strategy was evaluated with Src, a proto-oncogenic tyrosine kinase known to lose some enzymatic activity using the shape complementarity chemical genetic strategy. We found that Src with a cysteine gatekeeper recapitulates wild type activity and can be irreversibly inhibited both in vitro and in cells. A cocrystal structure of T338C c-Src with a vinylsulfonamide-derivatized pyrazolopyrimidine inhibitor was solved to elucidate the inhibitor binding mode. A panel of electrophilic inhibitors was analyzed against 307 kinases and MOK (MAPK/MAK/MRK overlapping kinase), one of only two human kinases known to have an endogenous cysteine gatekeeper. This analysis revealed remarkably few off-targets, making these compounds the most selective chemical genetic inhibitors reported to date. Protein engineering studies demonstrated that it is possible to increase inhibitor potency through secondary-site mutations. These results suggest that chemical genetic strategies based on covalent complementarity should be widely applicable to the study of protein kinases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This hydrophobic residue also touches the well-studied gate-keeper residue, which in PKA is M120; the gatekeeper is another shell residue (SH3) (Poulikakos et al., 2010;Garske et al., 2011).”
From Protein Kinase Structure and Dynamics: Role of the αC-β4 Loop (2023) · cites this paper as Garske et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
Powers, J. C., Asgian, J. L., Ekici, Ö. D., & James, K. E. (2002) · Chemical Reviews · doi:10.1021/cr010182v · Cited by 1,090
Sorafenib: a clinical and pharmacologic review
Iyer, R., Fetterly, G., Lugade, A., & Thanavala, Y. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.496453 · Cited by 169
Research works printed but not linked: 45
- J Zhang, PL Yang, NS Gray, Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9, 28–39 (2009). · DOI · Paper page
- DW Sherbenou, BJ Druker, Applying the discovery of the Philadelphia chromosome. J Clin Invest 117, 2067–2074 (2007). · DOI
- O Fedorov, S Muller, S Knapp, The (un)targeted cancer kinome. Nat Chem Biol 6, 166–169 (2010). · DOI · Paper page
- WA Weiss, SS Taylor, KM Shokat, Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat Chem Biol 3, 739–744 (2007). · DOI · Paper page
- SJ Rodig, GI Shapiro, Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Investig Dr 11, 1477–1490 (2010).
- PJ Alaimo, MA Shogren-Knaak, KM Shokat, Chemical genetic approaches for the elucidation of signaling pathways. Curr Opin Chem Biol 5, 360–367 (2001). · DOI
- Y Qiao, H Molina, A Pandey, J Zhang, PA Cole, Chemical rescue of a mutant enzyme in living cells. Science 311, 1293–1297 (2006). · DOI
- AC Bishop, et al., Design of allele-specific inhibitors to probe protein kinase signaling. Curr Biol 8, 257–266 (1998). · DOI · Paper page
- AC Bishop, et al., A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 407, 395–401 (2000). · DOI · Paper page
- KR Benjamin, C Zhang, KM Shokat, I Herskowitz, Control of landmark events in meiosis by the CDK Cdc28 and the meiosis-specific kinase Ime2. Genes Dev 17, 1524–1539 (2003). · DOI · Paper page
- EL Weiss, AC Bishop, KM Shokat, DG Drubin, Chemical genetic analysis of the budding-yeast p21-activated kinase Cla4p. Nat Cell Biol 2, 677–685 (2000). · DOI
- EM Rubenstein, et al., Access denied: Snf1 activation loop phosphorylation is controlled by availability of the phosphorylated threonine 210 to the PP1 phosphatase. J Biol Chem 283, 222–230 (2008). · DOI
- BB Au-Yeung, et al., A genetically selective inhibitor demonstrates a function for the kinase Zap70 in regulatory T cells independent of its catalytic activity. Nat Immunol 11, 1085–1092 (2010). · DOI
- QW Fan, C Zhang, KM Shokat, WA Weiss, Chemical genetic blockade of transformation reveals dependence on aberrant oncogenic signaling. Curr Biol 12, 1386–1394 (2002). · DOI
- T Okuzumi, et al., Inhibitor hijacking of Akt activation. Nat Chem Biol 5, 484–493 (2009). · DOI · Paper page
- PI Poulikakos, C Zhang, G Bollag, KM Shokat, N Rosen, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427–430 (2010). · DOI · Paper page
- AP Kornev, NM Haste, SS Taylor, LF Eyck, Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci USA 103, 17783–17788 (2006). · DOI · Paper page
- M Azam, MA Seeliger, NS Gray, J Kuriyan, GQ Daley, Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 15, 1109–1118 (2008). · DOI · Paper page
- C Zhang, et al., A second-site suppressor strategy for chemical genetic analysis of diverse protein kinases. Nat Methods 2, 435–441 (2005). · DOI
- AJ Cameron, C Escribano, AT Saurin, B Kostelecky, PJ Parker, PKC maturation is promoted by nucleotide pocket occupation independently of intrinsic kinase activity. Nat Struct Mol Biol 16, 624–630 (2009). · DOI
- K Levitsky, CJ Ciolli, PJ Belshaw, Selective inhibition of engineered receptors via proximity-accelerated alkylation. Org Lett 5, 693–696 (2003). · DOI
- K Levitsky, MD Boersma, CJ Ciolli, PJ Belshaw, Exo-mechanism proximity-accelerated alkylations: investigations of linkers, electrophiles and surface mutations in engineered cyclophilin-cyclosporin systems. Chembiochem 6, 890–899 (2005). · DOI
- MS Cohen, C Zhang, KM Shokat, J Taunton, Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science 308, 1318–1321 (2005). · DOI · Paper page
- JA Blair, et al., Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol 3, 229–238 (2007). · DOI · Paper page
- JR Simard, et al., A new screening assay for allosteric inhibitors of cSrc. Nat Chem Biol 5, 394–396 (2009). · DOI
- FM Richards, The interpretation of protein structures: total volume, group volume distributions and packing density. J Mol Biol 82, 1–14 (1974). · DOI · Paper page
- H Angliker, P Wikstrom, P Rauber, E Shaw, The synthesis of lysylfluoromethanes and their properties as inhibitors of trypsin, plasmin and cathepsin B. Biochem J 241, 871–875 (1987). · DOI
- AC Dar, MS Lopez, KM Shokat, Small molecule recognition of c-Src via the Imatinib-binding conformation. Chem Biol 15, 1015–1022 (2008). · DOI
- D Leung, G Abbenante, DP Fairlie, Protease inhibitors: current status and future prospects. J Med Chem 43, 305–341 (2000). · DOI · Paper page
- T Schindler, et al., Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol Cell 3, 639–648 (1999). · DOI · Paper page
- O Buzko, KM Shokat, A kinase sequence database: sequence alignments and family assignment. Bioinformatics 18, 1274–1275 (2002). · DOI · Paper page
- Y Miyata, M Akashi, E Nishida, Molecular cloning and characterization of a novel member of the MAP kinase superfamily. Genes Cells 4, 299–309 (1999). · DOI
- Y Miyata, Y Ikawa, M Shibuya, E Nishida, Specific association of a set of molecular chaperones including HSP90 and Cdc37 with MOK, a member of the mitogen-activated protein kinase superfamily. J Biol Chem 276, 21841–21848 (2001). · DOI
- F Zuccotto, E Ardini, E Casale, M Angiolini, Through the “gatekeeper door”: exploiting the active kinase conformation. J Med Chem 53, 2681–2694 (2010). · DOI · Paper page
- G Hatzivassiliou, et al., RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431–435 (2010). · DOI · Paper page
- JJ Reddick, J Cheng, WR Roush, Relative rates of Michael reactions of 2′-(phenethyl)thiol with vinyl sulfones, vinyl sulfonate esters, and vinyl sulfonamides relevant to vinyl sulfonyl cysteine protease inhibitors. Org Lett 5, 1967–1970 (2003). · DOI
- CB Breitenlechner, et al., Crystal structures of active SRC kinase domain complexes. J Mol Biol 353, 222–231 (2005). · DOI
- T Kortemme, NJ Darby, TE Creighton, Electrostatic interactions in the active site of the N-terminal thioredoxin-like domain of protein disulfide isomerase. Biochemistry 35, 14503–14511 (1996). · DOI
- AC Witt, et al., Cysteine pKa depression by a protonated glutamic acid in human DJ-1. Biochemistry 47, 7430–7440 (2008). · DOI
- T Kortemme, TE Creighton, Ionisation of cysteine residues at the termini of model alpha-helical peptides. Relevance to unusual thiol pKa values in proteins of the thioredoxin family. J Mol Biol 253, 799–812 (1995). · DOI · Paper page
- MS Cohen, H Hadjivassiliou, J Taunton, A clickable inhibitor reveals context-dependent autoactivation of p90 RSK. Nat Chem Biol 3, 156–160 (2007). · DOI
- DK Nomura, MM Dix, BF Cravatt, Activity-based protein profiling for biochemical pathway discovery in cancer. Nat Rev Cancer 10, 630–638 (2010). · DOI · Paper page
- MG Paulick, M Bogyo, Application of activity-based probes to the study of enzymes involved in cancer progression. Curr Opin Genet Dev 18, 97–106 (2008). · DOI
- DA Bachovchin, et al., Superfamily-wide portrait of serine hydrolase inhibition achieved by library-versus-library screening. Proc Natl Acad Sci USA 107, 20941–20946 (2010). · DOI · Paper page
- S Lourido, et al., Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma. Nature 465, 359–362 (2010). · DOI · Paper page
Cited by
Barf, T., Covey, T., Izumi, R., van de Kar, B., Gulrajani, M., van Lith, B., van Hoek, M., de Zwart, E., Mittag, D., Demont, D., et al. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242909 · Cited by 380
Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
Barf, T., & Kaptein, A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3003203 · Cited by 331
Advances in covalent kinase inhibitors
Abdeldayem, A., Raouf, Y. S., Constantinescu, S. N., Moriggl, R., & Gunning, P. T. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00720b · Cited by 317
Chemo- and Regioselective Lysine Modification on Native Proteins
Matos, M. J., Oliveira, B. L., Martínez-Sáez, N., Guerreiro, A., Cal, P. M. S. D., Bertoldo, J., Maneiro, M., Perkins, E., Howard, J., Deery, M. J., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b12874 · Cited by 314
Protein Kinase Structure and Dynamics: Role of the αC-β4 Loop
Wu, J., Jonniya, N. A., Hirakis, S. P., Olivieri, C., Veglia, G., Kornev, A. P., & Taylor, S. S. (2023) · doi:10.1101/2023.08.31.555822 · Cited by 17
Metadata
- Authors
- Garske, A. L., Peters, U., Cortesi, A. T., Perez, J. L., & Shokat, K. M.
- Affiliations
- Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California, 600 16th Street, MC 2280, San Francisco, CA 94158; and
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2011-08-18
- Volume
- 108
- Issue
- 37
- Pages
- 15046-15052
- ISSN
- 0027-8424
- 1091-6490
- Cited by
- 90
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chemical genetic strategy for targeting protein kinases based on covalent complementarity. https://app.cochat.ai/papers/10.1073/pnas.1111239108
- The paper
- Garske, A. L., Peters, U., Cortesi, A. T., Perez, J. L., & Shokat, K. M. (2011). Chemical genetic strategy for targeting protein kinases based on covalent complementarity. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1111239108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.